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Letters
RESEARCH LETTER
Evidence-BasedMedicine and the American Thoracic
Society Clinical Practice Guidelines
The American Thoracic Society (ATS) issues clinical practice
guidelines for the care of patients with pulmonary and critical
caredisease.TheutilityofATSguidelinesdependson thequal-
ity of the evidence base underpinning recommendations and
whether the guidelines per-
mit the practice of evidence-
based medicine (EBM).1,2
However, the extent to which ATS guidelines are substanti-
atedbyhigh-qualityevidenceandcanbeused topromoteEBM
is unknown.
Methods | Two of 3 investigators (R.C.S., K.D., and A.N.M.) re-
viewed each ATS clinical practice guideline recommenda-
tions listed on the ATS website as of August 1, 2017, that per-
tained to adults.3 We abstracted the following domains
necessary for evidence-based clinical decisionmaking based
onprior conceptual frameworks1,2: recommendation type, rec-
ommendation strength (using the Grading of Recommenda-
tionsAssessment,Development,andEvaluation[GRADE]scor-
ing system4 of strong [benefits clearly outweigh risks inmost
patients] vs low/conditional [benefits do not clearly out-
weigh risks in a substantial minority of patients]), quality of
evidence (using GRADE categories4 of high [further research
is unlikely to change estimate of effect] to very low [any esti-
mate of effect is uncertain]), EBMmeasures, and patient con-
text. Institutional review board approval was not needed be-
cause no human participants were included.
We defined recommendations as including the basic set
of EBM measures if they included at least 1 measure of test
performance for diagnostic recommendations (sensitivity,
specificity, or likelihood ratio) and at least 1 measure of abso-
lute benefit or harm for therapeutic recommendations (abso-
lute risk reduction/increase, number needed to treat/harm,
or relative risk with incidence of the outcome for the control
group). For patient context, we ascertained whether the nar-
rative text included any discussion of a person’s severity of
illness or comorbidities, sociopersonal context, prognosis, or
personal preference and how these domains might influence
the recommendation.1 Differences between reviewers were
resolved through negotiated consensus, aiming to achieve
agreement using the most inclusive definitions. Two-sided
P < .05 for descriptive statistics indicated significance.
Results | Among 222 unique recommendations from 16 sepa-
rate guidelines, 141 (63.5%) were based on low-quality evi-
dence, whereas fewer than 1 in 10 (19 [8.6%]) were based on
high-quality evidence (Table 1). Nonetheless, 86 (38.7%)were
designated strong recommendations. Higher quality of evi-
dencewas associatedwith an increased probability of receiv-
ing a strong recommendation; 29 of 141 low-quality evidence
recommendations (20.6%), 41 of 62 moderate-quality evi-
dence recommendations (66.1%), and 16 of 19 high-quality
evidence recommendations (84.2%) were strongly recom-
mended (P < .001 for trend). However, most strong recom-
mendationswere not supported by high-quality evidence (16
of 86 [18.6%]).
Of 52 diagnostic testing recommendations, 26 (50.0%)
presented the test’s sensitivity, specificity, or likelihood
ratios. Of 165 therapeutic recommendations, 76 (46.1%)
reported the treatment’s absolute benefits or harms. Overall,
101 recommendations (45.5%) included any discussion of
patient context, and this did not differ by recommendation
strength (61 [44.9%] for low/conditional vs 40 [46.5%] for
strong recommendations; P = .81) or quality of evidence (65
[46.1%] for low-, 29 [46.8%] for medium-, and 7 [36.8%] for
high-quality recommendations; P = .73). The most com-
monly discussed domains were severity of illness or comor-
bidities (84 [37.8%]) and sociopersonal context (51 [23.0%]).
Table 1. Summary of the Evidence Base for ATS Clinical Practice Guidelines
Recommendation
Type
Recommendations,
No.
Recommendations, No. (%)
Strengtha Quality of Evidenceb Meets Basic Definition
Strong Low/Conditional High Medium Low
EBM
Measures
Patient
Context
Overallc 222 86 (38.7) 136 (61.3) 19 (8.6) 62 (27.9) 141 (63.5) 102 (45.9) 101 (45.5)
Diagnostic 52 19 (36.5) 33 (63.5) 1 (1.9) 16 (30.8) 35 (67.3) 26 (50.0) 3 (5.8)
Therapeutic 165 65 (39.4) 100 (60.6) 18 (10.9) 44 (26.7) 103 (62.4) 76 (46.1) 98 (59.4)
Abbreviations: ATS, American Thoracic Society; EBM, evidence-basedmedicine.
a Classified using the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) score except the guideline for community-acquired
pneumonia (CAP), which used strong (most patients should receive the
intervention), medium, and weak (many health care professionals would not
follow this recommendation) categories. CAP recommendations of medium or
weak were reclassified as low/conditional.
b Classified using the 4 GRADE categories, combining low- and very-low-quality
ratings into a single low category, given the similar uncertainty and because
several ATS guidelines only used 1 of these categories.
c Includes diagnostic, therapeutic, screening (n = 3), andmonitoring (n = 3)
recommendations. One recommendation included both a therapeutic and
diagnostic recommendation.
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Prognosis (14 [6.3%]) and patient preference (3 [1.4%]) were
rarely discussed.
Guidelines varied considerably innumber, evidencebase,
and strength of recommendations (Table 2). The community-
acquired pneumonia guideline had the most recommenda-
tions (n = 47), had the highest proportion supported by high-
quality evidence (15 [31.9%]), and accounted for 15 of 19 total
recommendations supported by high-quality evidence.
Discussion | The ATS clinical practice guidelines are supported
by suboptimal evidence and often are not presented in a
manner suitable to optimize care for individual patients.
Although 38.7% of recommendations are strong, fewer than
1 in 10 are supported by high-quality evidence (ie, a random-
ized controlled trial or a meta-analysis). Apart from
community-acquired pneumonia, only 4 recommendations
were supported by high-quality evidence among the 175 rec-
ommendations for all other pulmonary and critical care con-
ditions combined.
The main limitation of our study was that we overesti-
mated the frequency that recommendations included EBM
measures andpatient contextdomains, becausewedidnot re-
quiremeaningful andcomplete information in theseareas.For
example, if a recommendation mentioned consideration of
costs, we credited the recommendation for including discus-
sion of a patient’s sociopersonal context.
Our studyhas several implications. First,mostATSguide-
lines should be cautiously applied and should not be consid-
ered standard of care, given the paucity of high-quality evi-
dence. Future randomized clinical trials could lead to reversal
of many recommendations, even for tests and therapies that
are currently strongly recommended.5 Further, standardiz-
ingpoorly substantiateddiagnostic testsor treatmentscan lead
to inappropriate andharmful care.6 Second, futureATSguide-
line committees should strive to adhere to best practices for
EBM,which includea transparentdiscussionofdiagnostic test
characteristics, treatment effectiveness, and relevant patient
contextdomains tohelpguideclinicaldecisionmaking.2Third,
our framework can be used by guideline development check-
lists and methodology reports to ensure future guidelines
adheres to EBM principles.
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Table 2. Summary of Evidence Base by Guideline
Disease Guideline (Year)
Recom-
menda-
tions, No.
Recommendations, No. (%)
Strength Quality of Evidence Meets Basic Definition
Strong Medium Low High Medium Low EBM
Patient
Context
Asthma, severe (2014) 9 1 (11.1) 0 8 (88.9) 0 0 9 (100) 4 (44.4) 3 (33.3)
Asthma, exercise-induced
(2013)
15 8 (53.3) 0 7 (46.7) 2 (13.3) 9 (60.0) 4 (26.7) 11 (73.3) 3 (20.0)
Bronchiolitis obliterans
(2014)
7 0 0 7 (100) 0 0 7 (100) 7 (100) 4 (57.1)
CAP treatment (2007) 47 20 (42.6) 23 (48.9) 4 (8.5) 15 (31.9) 12 (25.5) 20 (42.6) 5 (10.6) 22 (46.8)
COPD exacerbation (2017) 7 1 (14.3) 0 6 (85.7) 0 2 (28.6) 5 (71.4) 7 (100) 5 (71.4)
Stable COPD (2011) 9 6 (66.7) 0 3 (33.3) 0 8 (88.9) 1 (11.1) 0 2 (22.2)
Exhaled NO (2011) 11 7 (63.6) 0 4 (36.4) 0 5 (45.4) 6 (54.5) 2 (18.2) 0
HAP/VAP (2016) 45 19 (42.2) 0 26 (57.8) 0 7 (15.6) 38 (84.4) 13 (28.9) 28 (62.2)
ILD/IPF (2015) 10 4 (40.0) 0 6 (60.0) 0 4 (40.0) 6 (60.0) 9 (90.0) 6 (60.0)
LAM (2016) 5 2 (40.0) 0 3 (60.0) 0 2 (40.0) 3 (60.0) 3 (60.0) 0
pHTN in sickle cell (2011) 7 4 (57.1) 0 3 (42.9) 0 4 (57.1) 3 (42.8) 5 (71.4) 7 (100)
PE in pregnancy (2011) 8 3 (37.5) 0 5 (62.5) 0 0 8 (100) 1 (12.5) 0
Sleep apnea (2013) 4 1 (25.0) 0 3 (75.0) 0 1 (25.0) 3 (75.0) 0 3 (75.0)
TB diagnosis (2017) 20 5 (25.0) 0 15 (75.0) 0 4 (20.0) 16 (80.0) 17 (85.0) 1 (5.0)
TB treatment (2016) 14 5 (35.7) 0 9 (64.3) 2 (14.3) 3 (21.4) 9 (64.3) 14 (100) 14 (100)
Ventilator weaning (2017) 4 0 0 4 (100) 0 3 (75.0) 1 (25.0) 4 (100) 2 (50.0)
Abbreviations: CAP, community-acquired pneumonia; COPD, chronic
obstructive pulmonary disease; EBM, evidence-basedmedicine;
HAP/VAP, hospital-acquired pneumonia/ventilator-associated pneumonia;
ILD/IPF, interstitial lung disease/idiopathic pulmonary fibrosis;
LAM, lyphangioleiomyomatosis; NO, nitric oxide; pHTN, pulmonary
hypertension; PE, pulmonary embolism; TB, tuberculosis.
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